항체-약물 접합체란 무엇인가?
Review of Antibody-Drug Conjugates
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Antibody-drug conjugates (ADCs) are target-specific conjugates that consist of a monoclonal antibody connected to a cytotoxic payload using a stable linker. These conjugates combine the highly specific targeting ability and potent killing effect to accurately and efficiently eliminate cancer cells, which has ushered in a new era of targeted therapy. Since the first approval by the United States Food and Drug Administration in 2000, ADCs have experienced rapid development, with 14 of them receiving market approval. In this review, we examine the history, molecular structure, and pharmacological principles of ADCs, describing clinical trials and discussing the current challenges and future perspectives for the development of next-generation ADCs.
Abstract
Antibody-drug conjugates (ADCs) are target-specific conjugates that consist of a monoclonal antibody connected to a cytotoxic payload using a stable linker. These conjugates combine the highly specific targeting ability and potent killing effect to accurately and efficiently eliminate cancer cells, which has ushered in a new era of targeted therapy. Since the first approval by the United States Food and Drug Administration in 2000, ADCs have experienced rapid development, with 14 of them receiving market approval. In this review, we examine the history, molecular structure, and pharmacological principles of ADCs, describing clinical trials and discussing the current challenges and future perspectives for the development of next-generation ADCs.
참고문헌 (20)
- Fu Z, "Antibody drug conjugate : the"biological missile"for targeted cancer therapy", Signal Transduct Target Ther, 7, pp.93~ (2022)
- Su Z, "Antibody-drug conjugates : recent advances in linker chemistry", Acta Pharm Sin B, 11, pp.3889~3907 (2021)
- Kraynov E, "Current approaches for absorption, distribution, metabolism, and excretion characterization of antibody-drug conjugates : an industry white paper", Drug Metab Dispos, 44, pp.617~623 (2016)
- Peters C, "Antibody-drug conjugates as novel anti-cancer chemotherapeutics", Biosci Rep, 35, pp.e00225~ (2015)
- Damelin M, "Evolving strategies for target selection for antibody-drug conjugates", Pharm Res, 32, pp.3494~3507 (2015)
- Tumey LN, "An overview of the current ADC discovery landscape", Methods Mol Biol, 2078, pp.1~22 (2020)
- Staudacher AH, "Antibody drug conjugates and bystander killing : is antigen-dependent internalisation required?", Br J Cancer, 117, pp.1736~1742 (2017)
- Lambert JM, "Antibody-drug conjugates for cancer treatment", Annu Rev Med, 69, pp.191~207 (2018)
- Bargh JD, "Cleavable linkers in antibody-drug conjugates", Chem Soc Rev, 48, pp.4361~4374 (2019)
- Nolting B, "Linker technologies for antibody-drug conjugates", Methods Mol Biol, 1045, pp.71~100 (2013)
- Doronina SO, "Novel peptide linkers for highly potent antibody-auristatin conjugate", Bioconjug Chem, 19, pp.1960~1963 (2008)
- Kaur S, "Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics", Bioanalysis, 5, pp.201~226 (2013)
- Zhou Q, "Site-specific antibody conjugation with payloads beyond cytotoxins", Molecules, 28, pp.917~ (2023)
- Ruckhäberle E, "Trastuzumab emtansine vs. capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer", Onkologe, 23, pp.940~942 (2017)
- von Minckwitz G, "Trastuzumab emtansine for residual invasive HER2-positive breast cancer", N Engl J Med, 380, pp.617~628 (2019)
- Meddahi A, "FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives", Int J Biol Macromol, 18, pp.141~145 (1996)
- Modi S, "Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer : plain language summary of the DESTINY-Breast01 study", Future Oncol, 17, pp.3415~3423 (2021)
- Modi S, "Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer", N Engl J Med, 387, pp.9~20 (2022)
- Li BT, "Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer", N Engl J Med, 386, pp.241~251 (2022)
- Shitara K, "Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer", N Engl J Med, 382, pp.2419~2430 (2020)